Indegene Earnings Call: Key Takeaways
Indegene delivered strong FY26 revenue of INR 35,105M (+23.6% YoY) with steady 19.4% EBITDA margins, driven by GenAI-led transformation in life sciences.
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
37 announcements with these filters
Indegene delivered strong FY26 revenue of INR 35,105M (+23.6% YoY) with steady 19.4% EBITDA margins, driven by GenAI-led transformation in life sciences.
Indegene Ltd reported a landmark FY26 with annual revenue reaching ₹3,510.5 Crore, up 23.6% YoY. Q4 revenue crossed the ₹1,000 Crore milestone at ₹1,003.4 Crore with 32.8% growth. The Board recommended a final dividend of ₹2.25 per share. Management highlighted strong strategic depth with 53 clients contributing over $1M annually.
Indegene Ltd reported revenue from operations of ₹1,003 Cr (+32.8% YoY) and net profit of ₹79.7 Cr (-32.2% YoY) for Q4 FY26.
Indegene Limited reported audited FY26 consolidated revenue of ₹3,510.5 Crore and a net profit of ₹401.1 Crore. The Board recommended a final dividend of ₹2.25 per equity share, involving an outflow of ₹54.2 Crore. The company also approved policy amendments and ESOP allotments following its successful IPO during the year.
Indegene Limited has scheduled a board meeting for April 29, 2026, to consider audited standalone and consolidated financial results for the year ended March 2026. The board will also evaluate a recommendation for a final dividend. Trading window closure remains in effect until May 1, 2026.
Indegene Limited's Board of Directors will meet on April 29, 2026, to approve audited financial results for the year ended March 31, 2026. The Board will also consider recommending a final dividend and approving ESOP allotments. Consequently, the trading window is closed until 48 hours after the results declaration.
Indegene Ltd reported net profit of ₹103 Cr (-6.4% YoY) for Q3 FY26.